Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 13/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 12/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5999633 | 0.82 | HTR2A (0.62) | SLC6A4HTR2AKCNH2 | |
| SCHEMBL18004134 | 0.76 | NPC1 (0.49) | SLC6A4PKMTDP1DRD2NPC1 | |
| SCHEMBL5503447 | 0.72 | HTR2A (0.41) | SLC6A4HTR2AKCNH2MEN1KMT2A | |
| SCHEMBL593507 | 0.71 | NPC1 (0.54) | SLC6A4PKMTDP1DRD2NPC1 | |
| SCHEMBL14127183 | 0.71 | NPC1 (0.54) | SLC6A4PKMTDP1DRD2NPC1 | |
| SCHEMBL9845965 | 0.70 | DRD2 (0.45) | PKMTDP1DRD2NPC1RAB9A | |
| SCHEMBL5497556 | 0.69 | HTR2A (0.41) | SLC6A4HTR2AKCNH2MEN1KMT2A | |
| SCHEMBL5501871 | 0.69 | SLC6A4 (0.39) | SLC6A4HTR2AKCNH2 | |
| SCHEMBL5502199 | 0.69 | SLC6A4 (0.46) | SLC6A4HTR2AKCNH2 | |
| SCHEMBL5998632 | 0.69 | NOS1 (0.51) | SLC6A4TDP1HTR2AKCNH2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | SLC6A4 150/4885PKM 1621/4885TDP1 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.